E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

被引：0
|
作者：
Hochster, Howard S.
Catalano, Paul J.
Mitchell, Edith P.
Cohen, Deirdre Jill
O'Dwyer, Peter J.
Benson, Al Bowen
机构：
[1] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[4] NYU, Inst Canc, New York, NY USA
[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3665
引用
收藏
页数：1
相关论文
共 50 条
  • [1] E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC).
    Hochster, Howard S.
    Catalano, Paul J.
    Mitchell, Edith P.
    Cohen, Deirdre Jill
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208
    Hochster, H.
    Catalano, Paul J.
    O'Dwyer, Peter J.
    Mitchell, Edith P.
    Cohen, Deirdre Jill
    Faller, Bryan Andrew
    Kortmansky, Jeremy S.
    Kircher, Sheetal Mehta
    Lacy, Jill
    Lenz, Heinz-Josef
    Verma, Udit N.
    Benson, Al Bowen, III
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.
    Hochster, Howard S.
    Catalano, Paul J.
    O'Dwyer, Peter J.
    Mitchell, Edith P.
    Cohen, Deirdre Jill
    Faller, Bryan Andrew
    Kortmansky, Jeremy S.
    Kircher, Sheetal Mehta
    Lacy, Jill
    Lenz, Heinz-Josef
    Verma, Udit N.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS
    Hong, Yong Sang
    Kim, Hwa Jung
    Park, Seong Joon
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Park, Jin Hong
    Kim, Jong Hoon
    Lim, Seok-Byung
    Yu, Chang Sik
    Kim, Jin Cheon
    Baek, Ji Yeon
    Kim, Sun Young
    Kim, Tae Won
    CANCER SCIENCE, 2013, 104 (04) : 473 - 480
  • [5] Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
    ELez, E.
    Kocakova, I.
    Hoehler, T.
    Martens, U. M.
    Bokemeyer, C.
    Van Cutsem, E.
    Melichar, B.
    Smakal, M.
    Csoszi, T.
    Topuzov, E.
    Orlova, R.
    Tjulandin, S.
    Rivera, F.
    Straub, J.
    Bruns, R.
    Quaratino, S.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 132 - 140
  • [6] Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
    Townsend, Amanda
    Tebbutt, Niall
    Karapetis, Christos
    Cooper, Pamela
    Singhal, Nimit
    Yeend, Susan
    Pirc, Louise
    Joshi, Rohit
    Hardingham, Jennifer
    Price, Timothy
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3838 - 3844
  • [7] Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer
    Osumi, Hiroki
    Shinozaki, Eiji
    Mashima, Tetsuo
    Wakatsuki, Takeru
    Suenaga, Mitsukuni
    Ichimura, Takashi
    Ogura, Mariko
    Ota, Yumiko
    Nakayama, Izuma
    Takahari, Daisuke
    Chin, Keisho
    Miki, Yoshio
    Yamaguchi, Kensei
    CANCER SCIENCE, 2018, 109 (08) : 2567 - 2575
  • [8] Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients
    Terazawa, Tetsuji
    Nishitani, Hitoshi
    Kato, Ken
    Hashimoto, Hironobu
    Akiyoshi, Kohei
    Ito, Yuriko
    Nakamoto, Akihiro
    Iwasa, Satoru
    Nakajima, Takako Eguchi
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E132 - E137
  • [9] Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)
    Hochster, Howard S.
    Catalano, Paul
    Weitz, Michelle
    Mitchell, Edith P.
    Cohen, Deirdre
    O'Dwyer, Peter J.
    Faller, Bryan A.
    Kortmansky, Jeremy S.
    O'Hara, Mark H.
    Kricher, Sheetal M.
    Lacy, Jill
    Lenz, Heinz-Josef
    Verma, Udit
    Benson, Al B.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (09):
  • [10] Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study
    Iwamoto, Shigeyoshi
    Hazama, Shoichi
    Kato, Takeshi
    Miyake, Yasuhiro
    Fukunaga, Mutsumi
    Matsuda, Chu
    Bando, Hiroyuki
    Sakamoto, Junichi
    Oba, Koh
    Mishima, Hideyuki
    ANTICANCER RESEARCH, 2014, 34 (04) : 1967 - 1973
12345